ALNY
Alnylam Pharmaceuticals, Inc.
Stock
$219.72−11.46 (−4.96%)Close Oct 2, 2026
- Research and development, 2025
- $1.3B
- YoY, 2025
- +17.2%
- 5-year CAGR
- +15.0%
- 10-year CAGR
- +16.9%
Research and development
Research and development by fiscal year
| Period | R&D | YoY |
|---|---|---|
| 2025 | $1.3B | +17.2% |
| 2024 | $1.1B | +12.1% |
| 2023 | $1.0B | +13.7% |
| 2022 | $883M | +11.5% |
| 2021 | $792M | +21.0% |
| 2020 | $655M | 0.0% |
| 2019 | $655M | +29.6% |
| 2018 | $505M | +29.4% |
| 2017 | $391M | +2.2% |
| 2016 | $382M | +38.3% |
| 2015 | $276M | +45.3% |
| 2014 | $190M | +68.4% |
| 2013 | $113M | +30.5% |
| 2012 | $87M | −12.8% |
| 2011 | $99M | −6.7% |
| 2010 | $106M | −2.2% |
| 2009 | $109M | +12.2% |
| 2008 | $97M | — |